Lacutamab in Patients with Relapsed and Refractory Sèzary Syndrome: Results from the Tellomak Phase 2 Trial

Bagot, M., Kim, Y. H., Geskin, L. J., Ortiz-Romero, P. L., Kim, E., Mehta-Shah, N., Dereure, O., Oro, S., Beylot-Barry, M., Dalle, S., Jacobsen, E., Lansigan, F., Ram-Wolff, C., Khodadoust, M. S., Battistella, M., Gru, A. A., Moins-Teisserenc, H., Zinzani, P. L., Viotti, J., … Porcu, P. (2023). Lacutamab in Patients with Relapsed and Refractory Sèzary Syndrome: Results from the Tellomak Phase 2 Trial. Blood, 142(Supplement 1), 185–185. https://doi.org/10.1182/blood-2023-173806
Authors:
M. Bagot
Youn H. Kim
Larisa J. Geskin
Pablo L. Ortiz‐Romero
Ellen Kim
Neha Mehta‐Shah
O. Dereure
S. Oro
M. Beylot‐Barry
Stéphane Dalle
Eric Jacobsen
Frederick Lansigan
C. Ram‐Wolff
Michael S. Khodadoust
Maxime Battistella
Alejandro A. Gru
Hélène Moins‐Teisserenc
Pier Luigi Zinzani
Julien Viotti
Christine Paiva
Marianna Müller
Pierluigi Porcu
Affiliated Authors:
Larisa J. Geskin
Columbia Affiliation:
Subjects:
Classification and Treatment of Cutaneous Lymphomas (OpenAlex Topic)
Immunotoxin Therapy for Cancer Treatment (OpenAlex Topic)
Lymphoid Neoplasms (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1182/blood-2023-173806
DOI:
10.1182/blood-2023-173806
Journal:
Blood
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: